MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2018.07.09
- Author:
Limei YIN
1
;
You LU
1
Author Information
1. Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- Keywords:
Crizotinib;
Lung neoplasms;
MET;
Targeted therapy;
Tyrosine kinase inhibitors
- MeSH:
Carcinoma, Non-Small-Cell Lung;
drug therapy;
genetics;
Exons;
genetics;
Humans;
Lung Neoplasms;
drug therapy;
genetics;
Molecular Targeted Therapy;
Mutation;
Proto-Oncogene Proteins c-met;
genetics
- From:
Chinese Journal of Lung Cancer
2018;21(7):553-559
- CountryChina
- Language:Chinese
-
Abstract:
Recently, targeted therapy has achieved great success in the treatment of non-small cell lung cancer (NSCLC) patients. Mesenchymal to epithelial transition factor (MET) is considered to be another important molecular target for NSCLC since epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Accumulating clinical trials and case reports have confirmed that MET inhibitors exhibited a potential prospect in treating patients with MET 14 exon skipping alterations, suggesting that MET 14 exon skipping mutation might be an effective biomarker for MET inhibitors, which remains to be confirmed by more clinical data. This review summarizes current research about the molecular mechanism, clinicopathological characterization, treatment strategies and drug resistance mechanisms of MET 14 exon skipping alterations in NSCLC.
.
